DCTH Delcath Systems Inc
Price (delayed)
$9.83
Market cap
$275.24M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.4
Enterprise value
$266.04M
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT™ (melphalan hydrochloride for injection/hepatic delivery system), is
Highlights
Delcath Systems's gross profit has soared by 182% from the previous quarter
The company's revenue has surged by 158% QoQ
DCTH's quick ratio is up by 45% year-on-year but it is down by 11% since the previous quarter
Delcath Systems's equity has plunged by 71% from the previous quarter
The net income has plunged by 68% YoY and by 13% from the previous quarter
Key stats
What are the main financial stats of DCTH
Market
Valuations
Earnings
Shares outstanding
28M
Market cap
$275.24M
Enterprise value
$266.04M
Price to earnings (P/E)
N/A
Price to book (P/B)
65.16
Price to sales (P/S)
23.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
22.4
Revenue
$11.88M
EBIT
-$55.67M
EBITDA
-$55.42M
Free cash flow
-$31.51M
Per share
Balance sheet
Liquidity
EPS
-$2.4
Free cash flow per share
-$1.11
Book value per share
$0.15
Revenue per share
$0.42
TBVPS
$1.2
Total assets
$33.91M
Total liabilities
$29.72M
Debt
$5.58M
Equity
$4.19M
Working capital
$19.11M
Debt to equity
1.33
Current ratio
2.55
Quick ratio
1.92
Net debt/EBITDA
0.17
Margins
Efficiency
Dividend
EBITDA margin
-466.6%
Gross margin
77.1%
Net margin
-474.2%
Operating margin
-303.5%
Return on assets
-144.2%
Return on equity
-379.9%
Return on invested capital
-407.9%
Return on capital employed
-257.4%
Return on sales
-468.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DCTH stock price
How has the Delcath Systems stock price performed over time
Intraday
-1.31%
1 week
-5.93%
1 month
31.59%
1 year
104.37%
YTD
136.3%
QTD
17.44%
Financial performance
How have Delcath Systems's revenue and profit performed over time
Revenue
$11.88M
Gross profit
$9.15M
Operating income
-$36.05M
Net income
-$56.33M
Gross margin
77.1%
Net margin
-474.2%
Delcath Systems's gross profit has soared by 182% from the previous quarter
The company's revenue has surged by 158% QoQ
DCTH's operating margin has surged by 75% year-on-year and by 65% since the previous quarter
The net income has plunged by 68% YoY and by 13% from the previous quarter
Growth
What is Delcath Systems's growth rate over time
Valuation
What is Delcath Systems stock price valuation
P/E
N/A
P/B
65.16
P/S
23.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
22.4
Delcath Systems's EPS has increased by 24% YoY and by 4% from the previous quarter
Delcath Systems's equity has plunged by 71% from the previous quarter
The company's revenue has surged by 158% QoQ
The price to sales (P/S) is 15% less than the last 4 quarters average of 28.0 but 10% more than the 5-year quarterly average of 21.6
Efficiency
How efficient is Delcath Systems business performance
Delcath Systems's ROS has soared by 60% YoY and by 56% from the previous quarter
The company's return on invested capital rose by 24% YoY
The ROE is down by 4.7% since the previous quarter
The ROA has decreased by 3.8% QoQ but it has increased by 3.6% YoY
Dividends
What is DCTH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DCTH.
Financial health
How did Delcath Systems financials performed over time
The total assets is 14% greater than the total liabilities
The total assets has soared by 61% year-on-year but it has declined by 6% since the previous quarter
Delcath Systems's current ratio has increased by 46% YoY
Delcath Systems's debt is 33% higher than its equity
DCTH's debt to equity has soared by 129% QoQ and by 103% YoY
Delcath Systems's equity has plunged by 71% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.